CD7 CAR-T cells for hard-to-treat scleroderma
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new type of cell therapy called CD7 CAR-T cells for people with systemic sclerosis (a form of scleroderma) that hasn't responded to standard treatments. The goal is to see if these special immune cells can help calm the overactive immune system and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have systemic sclerosis that has come back or not improved after at least two prior treatments.
- Your major organs (like bone marrow, liver, kidneys, heart, and lungs) are working well enough.
- You do not have other cancers within the past 5 years.
- You are free from active infections like hepatitis B, AIDS, or syphilis.
- You do not have severe heart disease or serious mental health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
This study tests a new cell therapy called CD19 CAR-T for patients with systemic sclerosis that hasn't improved with standard treatments. The therapy aims to help reduce skin tightening and other symptoms.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new type of cell therapy (4SCAR7U) designed to target and kill cancer cells that carry a protein called CD7. It is for people with blood cancers that have not responded to other treatments.
Hear when a new Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.